复合式冷热消融系统治疗原发性肝癌中国专家共识(2023)

Chinese expert consensus on Co-Ablation System for the treatment of primary liver cancer(2023 edition)

局部消融术后复发和转移是影响肝癌患者远期生存的主要因素。新一代复合式冷热消融系统(康博刀)整合了深低温冷消融和热消融的优点,彻底破坏原位肝癌的同时最大程度释放肿瘤抗原,以达到控制肝癌复发和转移的目的。复合式冷热消融通常在超声或CT引导下经皮穿刺进行,根据肿瘤大小及部位选择局部麻醉或全身麻醉方式,主要适合于单发肿瘤直径<5 cm,多发肿瘤(≤3枚)最大直径<3 cm者。术后根据情况给予保肝及对症等治疗,1个月左右通过肝脏MRI或增强CT评估疗效并进入后期随访。为规范复合式冷热消融系统在肝癌中的应用,经中国抗癌协会肿瘤微创治疗专业委员会和肿瘤消融治疗专业委员会肝癌消融治疗专家充分讨论后达成本专家共识。

Clinically,the recurrence and metastasis of liver cancer after local ablation therapy have been the main factors affecting the long-term survival of patients with liver cancer.As a new generation of composite cryoablation and thermal ablation system,Co-Ablation System creatively integrates the advantages of profound hypothermia cryoablation and thermal ablation,which can maximize the release of tumor antigen while completely destroying liver cancer in situ,thus,the purpose of controlling liver cancer recurrence and metastasis can be achieved.Co-Ablation System treatment is usually carried out through percutaneous puncture under ultrasound or CT guidance.The selection of local anesthesia or general anesthesia is based on the size and location of the liver cancer.Co-Ablation System treatment is mainly suitable for single tumor with diameter<5 cm and multiple tumors(≤3 tumor lesions)with a maximum diameter<3 cm.After ablation,protection of liver function and symptomatic treatment are employed according to patient’s condition.About one month after ablation,MRI or contrast-enhanced CT examination is performed to evaluate the therapeutic efficacy,then,the patients are followed up regularly.In order to standardize the application of Co-Ablation System in treating liver cancer,the Committee of Minimally Invasive Therapy in Oncology and the Committee of Ablation Therapy in Oncology,Chinese Anti-Cancer Association,have organized domestic experts engaged in liver cancer ablation therapy to make a professional and in-depth discussion and to compose this expert consensus on Co-Ablation System for the treatment of primary liver cancer.